Brendan Kelly

Brendan Kelly, PhD, has a wealth of experience in the life sciences industry. Currently serving as Vice President at Lightstone Ventures, Brendan previously held key roles at companies such as A2A Pharmaceuticals and Q32 Bio Inc. Brendan also worked as a Life Sciences Consultant at L.E.K. Consulting and conducted postdoctoral research at Stanford University and University Health Network. Brendan's research focuses on drug discovery and optimization, particularly in the field of neurological drugs targeting G protein-coupled receptors (GPCRs).